Participants 221 348 7
in patients with epithelial ovarian carcinoma that recurred after or didn't respond to first-line, platinum-based chemotherapy.
Participants 370 417 7
Patients with measurable and assessable disease
Participants 689 754 8
A total of 474 patients were treated (239 PLD and 235 topotecan).
